Inicio / Oncología / Abstracts de oncología / Immuno-Oncological Treatment…

Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice

0 / 5 (0 votos)
Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice

Oncology: International Journal of Cancer Research and Treatment

Fecha de publicación: October 2019

DOI: https://doi.org/10.1159/000500885

Autores: Faehling M., Kopp M., Schwenk B., Fallscheer S., Kramberg S., Eckert R.

Background: Immuno-oncological (IO) therapies such as PD-1 and PD-L1 antibodies have been introduced in the treatment of advanced non-small cell lung cancer (NSCLC) since 2015 based on randomized trials showing unprecedented advantages in overall survival (OS) with hazard ratios (HRs) between 0.5 and 0.7. The impact of these treatments on OS in routine clinical practice and the role of tumor mass have not been studied.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.